spacer
home > ebr > > proteolytic enzymes as therapeutic targets
PUBLICATIONS
European Biopharmaceutical Review

Proteolytic Enzymes as Therapeutic Targets

The regulation of protein secretion is central to the proper functioning of eukaryotic organisms. One mode of protein secretion is the generation of soluble fragments of membrane-bound proteins by limited proteolysis through the action of proteases termed secretases, or sheddases. In general, cleavage occurs close to the extracellular face of the membrane, releasing active protein. Proteins secreted in this fashion include some membrane receptors and receptor ligands, ectoenzymes and cell adhesion molecules. Since the proteins concerned are involved in pathophysiological processes, such as neurodegeneration, inflammation and oncogenesis, inhibitors of respective secretases are emerging as promising therapeutic drugs. This article will review a number of methods that have allowed molecular cloning of secretases and discuss different approaches to discovering specific secretase inhibitors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Urs Lüthi, Senior Scientist at ESBATech

Dr Urs Lüthi carried out his PhD studies at ESBATech under the supervision of Dr Alcide Barberis and has recently completed his dissertation on the subject of functional screening systems in yeast to identify secretases, targets of secretases and modulators of secretase activity. An essential part of his work focused on the development of the cellular assay for BACE activity that is further developed for small compound inhibitors screens.
He will continue to develop his expertise as a Senior Scientist with ESBATech and will be responsible for the development of similar cell-based assay systems. Urs' academic work was presented at several international conferences and published in peer-reviewed journals.

spacer
Dr Urs Lüthi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

INC Research Demonstrates Continued Dedication to Site Relationships at 2014 SCRS Site Solutions Summit

Raleigh, N.C., Oct. 2, 2014 - INC Research, a leading, global Phase I to IV clinical research organization (CRO), today announced plans for an extensive presence at the 2014 Society for Clinical Research Sites (SCRS) Site Solutions Summit taking place Oct. 10-12, 2014, on Amelia Island, Fla. Recognizing the critical role clinical research sites play in bringing new medicines to market for patients, the Company will be maximizing the opportunities available at the SCRS Summit to deepen its connections with this important stakeholder group and contribute to the ongoing dialogue on how CROs and sites can work more effectively together for the benefit of sponsors and patients.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 
Industry Events

Annual World Drug Manufacturing Summit

1-3 December 2014, Berlin, Germany

Now in its 13th year, the World Drug Manufacturing Summit provides the key tools to overcome the biggest threats facing pharma manufacturers today.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement